Adial Pharmaceuticals (ADIL) Competitors

Equillium (NASDAQ:EQ) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Which has more risk and volatility, EQ or ADIL?

Equillium has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.

Is EQ or ADIL more profitable?

Adial Pharmaceuticals has a net margin of 0.00% compared to Equillium's net margin of -19.62%. Equillium's return on equity of -114.69% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	-19.62%	-114.69%	-78.89%
Adial Pharmaceuticals	N/A	-191.31%	-153.59%

Which has preferable valuation and earnings, EQ or ADIL?

Equillium has higher revenue and earnings than Adial Pharmaceuticals. Equillium is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	1.16	-$8.07M	-$0.56	-2.37
Adial Pharmaceuticals	N/A	N/A	-$13.20M	-$1.05	-0.35

Do analysts recommend EQ or ADIL?

Equillium currently has a consensus price target of $3.00, suggesting a potential upside of 125.73%. Adial Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 2,091.78%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Adial Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Do institutionals & insiders hold more shares of EQ or ADIL?

27.1% of Equillium shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 30.3% of Equillium shares are owned by insiders. Comparatively, 4.3% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media favor EQ or ADIL?

In the previous week, Equillium and Equillium both had 6 articles in the media. Adial Pharmaceuticals' average media sentiment score of 0.71 beat Equillium's score of 0.23 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adial Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Equillium beats Adial Pharmaceuticals on 8 of the 14 factors compared between the two stocks.